NAS:MYGN (USA) Also trade in: Germany UK

Myriad Genetics Inc

$ 25.77 -0.29 (-1.11%)
On watch
Volume: 50,281 Avg Vol (1m): 993,727
Market Cap $: 1.89 Bil Enterprise Value $: 2.01 Bil
P/E (TTM): 89.05 P/B: 1.75
Earnings Power Value 23.15
Net Current Asset Value -1.77
Tangible Book -0.45
Projected FCF 27.8
Median P/S Value 45.52
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 6.7/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.57
Cash-To-Debt range over the past 10 years
Min: 0.57, Med: 10000, Max: 10000
Current: 0.57
0.57
10000
Equity-to-Asset 0.70
Equity-to-Asset range over the past 10 years
Min: 0.57, Med: 0.89, Max: 0.96
Current: 0.7
0.57
0.96
Debt-to-Equity 0.24
Debt-to-Equity range over the past 10 years
Min: 0, Med: 0.01, Max: 0.28
Current: 0.24
0
0.28
Debt-to-EBITDA 2.58
Debt-to-EBITDA range over the past 10 years
Min: 0.05, Med: 0.55, Max: 2.58
Current: 2.58
0.05
2.58
Interest Coverage 2.97
Interest Coverage range over the past 10 years
Min: 2.97, Med: 10000, Max: 10000
Current: 2.97
2.97
10000
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.40
DISTRESS
GREY
SAFE
Beneish M-Score -2.83
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 2.58%
WACC 9.85%

Profitability & Growth : 7/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 3.39
Operating Margin range over the past 10 years
Min: 3.39, Med: 35.81, Max: 39.24
Current: 3.39
3.39
39.24
Net Margin % 2.45
Net Margin range over the past 10 years
Min: 2.45, Med: 22.63, Max: 42
Current: 2.45
2.45
42
ROE % 2.03
ROE range over the past 10 years
Min: 2.03, Med: 18.28, Max: 30.71
Current: 2.03
2.03
30.71
ROA % 1.48
ROA range over the past 10 years
Min: 1.48, Med: 16.98, Max: 28.73
Current: 1.48
1.48
28.73
ROC (Joel Greenblatt) % 27.94
ROC (Joel Greenblatt) range over the past 10 years
Min: 27.94, Med: 252.61, Max: 362.64
Current: 27.94
27.94
362.64
3-Year Total Revenue Growth Rate 2.20
3-Year Revenue Growth Rate range over the past 10 years
Min: 1.6, Med: 19.65, Max: 45.7
Current: 3.4
1.6
45.7
3-Year Total EBITDA Growth Rate 2.90
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -2.45, Max: 33.6
Current: 4.1
0
33.6
3-Year EPS w/o NRI Growth Rate 19.00
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -3.45, Max: 26.9
Current: 19
0
26.9

» MYGN's 30-Y Financials

Financials (Next Earnings Date: 2019-08-14)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:MYGN

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Diagnostics & Research » Medical Diagnostics & Research    NAICS : 325413    SIC : 2835
Compare SZSE:300463 NAS:NEO NAS:GHDX NAS:NTRA NYSE:NVTA SZSE:300482 SHSE:603882 BSP:FLRY3 BSP:DASA3 NAS:MEDP NAS:QDEL NAS:BEAT SZSE:300244 NAS:CDNA OSTO:SECT B TSE:4544 NSE:LALPATHLAB NAS:AXDX TSE:4694 NAS:VREX
Traded in other countries MYD.Germany 0K3W.UK
Address 320 Wakara Way, Salt Lake City, UT, USA, 84108
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease or tailor treatment for already diagnosed patients. The firm produces myRisk, a 28-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysis CDx, GeneSight, Vectra DA, and Prolaris. The firm also offers biomarker discovery and companion diagnostic services to pharmaceutical and biotechnology companies.

Ratios

Current vs industry vs history
PE Ratio (TTM) 89.05
PE Ratio range over the past 10 years
Min: 9.1, Med: 20.19, Max: 118.41
Current: 89.05
9.1
118.41
Forward PE Ratio 15.70
N/A
PE Ratio without NRI 89.05
PE without NRI range over the past 10 years
Min: 9.1, Med: 19.38, Max: 118.41
Current: 89.05
9.1
118.41
Price-to-Owner-Earnings 61.51
Price-to-Owner-Earnings range over the past 10 years
Min: 9.53, Med: 23.98, Max: 115.39
Current: 61.51
9.53
115.39
PB Ratio 1.75
PB Ratio range over the past 10 years
Min: 1.46, Med: 3.25, Max: 8.23
Current: 1.75
1.46
8.23
PS Ratio 2.28
PS Ratio range over the past 10 years
Min: 1.51, Med: 3.94, Max: 14.75
Current: 2.28
1.51
14.75
Price-to-Free-Cash-Flow 21.13
Price-to-Free-Cash-Flow range over the past 10 years
Min: 7.6, Med: 17.09, Max: 44.47
Current: 21.13
7.6
44.47
Price-to-Operating-Cash-Flow 19.13
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 7.21, Med: 16.18, Max: 44
Current: 19.13
7.21
44
EV-to-EBIT 61.99
EV-to-EBIT range over the past 10 years
Min: 4.4, Med: 14.1, Max: 91.3
Current: 61.99
4.4
91.3
EV-to-EBITDA 19.65
EV-to-EBITDA range over the past 10 years
Min: 4.3, Med: 11.8, Max: 36.2
Current: 19.65
4.3
36.2
EV-to-Revenue 2.42
EV-to-Revenue range over the past 10 years
Min: 1.5, Med: 3.4, Max: 13.6
Current: 2.42
1.5
13.6
Shiller PE Ratio 17.72
Shiller PE Ratio range over the past 10 years
Min: 12.33, Med: 38.32, Max: 2553
Current: 17.72
12.33
2553
Current Ratio 3.15
Current Ratio range over the past 10 years
Min: 1.17, Med: 5.68, Max: 20.28
Current: 3.15
1.17
20.28
Quick Ratio 2.86
Quick Ratio range over the past 10 years
Min: 0.98, Med: 5.64, Max: 20.28
Current: 2.86
0.98
20.28
Days Inventory 62.81
Days Inventory range over the past 10 years
Min: 32.11, Med: 58.27, Max: 85.81
Current: 62.81
32.11
85.81
Days Sales Outstanding 60.63
Days Sales Outstanding range over the past 10 years
Min: 38.41, Med: 45.42, Max: 60.63
Current: 60.63
38.41
60.63
Days Payable 44.83
Days Payable range over the past 10 years
Min: 44.83, Med: 65.18, Max: 119.6
Current: 44.83
44.83
119.6

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -0.80
3-Year Share Buyback Rate range over the past 10 years
Min: -13.6, Med: -4.25, Max: 5.9
Current: -0.8
-13.6
5.9

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 0.93
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 0.48, Med: 1.13, Max: 64.23
Current: 0.93
0.48
64.23
Price-to-Median-PS-Value 0.57
Price-to-Median-PS-Value range over the past 10 years
Min: 0.41, Med: 1.43, Max: 11.51
Current: 0.57
0.41
11.51
Earnings Yield (Joel Greenblatt) % 1.60
Earnings Yield (Greenblatt) range over the past 10 years
Min: 1.1, Med: 7.1, Max: 22.7
Current: 1.6
1.1
22.7
Forward Rate of Return (Yacktman) % -7.96
Forward Rate of Return range over the past 10 years
Min: -9.1, Med: 3.1, Max: 27.9
Current: -7.96
-9.1
27.9

More Statistics

Revenue (TTM) (Mil) $ 858.5
EPS (TTM) $ 0.29
Beta 1.38
Volatility % 49.11
52-Week Range $ 22.07 - 50.44
Shares Outstanding (Mil) 73.2

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y